 Home > Active Ingredient News > Antitumor Therapy > CDE issued soliciting opinions on CAR-T guidelines

CDE issued soliciting opinions on CAR-T guidelines

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

waste management problems

rosedale products

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Chimeric antigen receptor T cell therapy products have the characteristics of novelty, complexity and technical specificity.
With the development of such products and the successive application for listing, they can promote the early detection of the risks of such products and provide effective risks.
Minimal measures to ensure that the safety risk is controllable after listing, and it is necessary to put forward requirements and provide guidance on the clinical risk management plan for applying for listing
.

On the basis of thorough investigation, our center drafted the " Technical Guidelines for the Clinical Risk Management Plan for the Application of Chimeric Antigen Receptor T Cells ( CAR-T ) Products (Draft for Comment)"

Manage CAR-T

We sincerely welcome valuable comments and suggestions from all walks of life on the solicitation draft, and timely feedback to us for follow-up improvement
.

The time limit for soliciting opinions is 1 month from the date of publication

Please send your feedback to the mailbox of the following contact:

Contact: Huang Yunhong, Zhao Chenyang

Contact: huangyh@cde.

Thank you for your participation and great support

Drug Evaluation Center of the State Drug Administration

September 18, 2021

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.